Table 1 Baseline characteristics of patients after 1–8 years of SVS (cohort 1)

Sex(male,%)

3606 (68.9%)

3135 (67.3%)

471 (82.2%)

< 0.001

Age(years)

46 (37, 56)

45 (36, 55)

56 (49, 62)

< 0.001

 <40

1822 (34.8%)

1777 (38.1%)

45 (7.9%)

< 0.001

 ≥40

3412 (65.2%)

2884 (61.9%)

528 (92.1%)

Hypertension

772 (14.7%)

614 (13.2%)

158 (27.6%)

< 0.001

DM (%)

504 (9.6%)

380 (8.2%)

124 (21.6%)

< 0.001

kidney disease

260 (5.0%)

233 (5.0%)

27 (4.7%)

0.77

Dyslipidaemia (%)

590 (11.3%)

550 (11.8%)

40 (7.0%)

< 0.001

BMI (kg/m2)

22.32 (20.73, 24.57)

22.32 (20.63, 24.49)

22.96 (21.36, 25.26)

< 0.001

 <25

4111 (78.5%)

3696 (79.3%)

415 (72.4%)

< 0.001

 ≥25

1123 (21.5%)

965 (20.7%)

158 (27.6%)

AST (U/L)

41 (24, 72)

41 (24, 73)

41 (28, 66)

0.43

ALT (U/L)

37 (26, 58)

37 (26, 58)

41 (30, 61)

< 0.001

γ-GT (U/L)

45 (23, 92)

43 (22, 88)

62 (36, 107)

< 0.001

 <56

3060 (58.5%)

2797 (60.0%)

263 (45.9%)

< 0.001

 ≥56

2174 (41.5%)

1864 (40.0%)

310 (54.1%)

Total bilirubin (g/l)

13 (9, 19)

12 (9, 19)

14 (10, 21)

< 0.001

Albumin (g/dl)

38.85 (34.2, 43)

38.9 (34.3, 43.1)

38.2 (33.2, 42.7)

0.016

Platelet (×10^9/L)

159 (107, 201)

161 (113, 204)

123 (82, 161)

< 0.001

WBC (×10^9/L)

5.36 (4.21, 6.58)

5.36 (4.24, 6.59)

5.3 (3.98, 6.43)

0.036

FIB-4 score

1.78 (1.04, 3.41)

1.67 (1, 3.13)

3.08 (1.8, 5.66)

< 0.001

 ≤ 3.25

3854 (73.6%)

3554 (76.2%)

300 (52.4%)

< 0.001

 >3.25

1380 (26.4%)

1107 (23.8%)

273 (47.6%)

APRI score

0.62 (0.35, 1.2)

0.60 (0.34, 1.16)

0.78(0.48, 1.53)

< 0.001

 <2

4576 (87.4%)

4110 (88.2%)

466 (81.3%)

< 0.001

 ≥2

658 (12.6%)

551 (11.8%)

107 (18.7%)

ALBI score

-2.58 (-2.97, -2.12)

-2.59 (-2.98, -2.14)

-2.49 (-2.89, -2.02)

0.002

 <-2.60)

2534 (48.4%)

2285 (49.0%)

249 (43.5%)

0.012

 ≥-2.60

2700 (51.6%)

2376 (51.0%)

324 (56.5%)

Creatinine (mg/dl)

66 (55, 75)

66 (55, 75)

66 (57, 75)

0.24

eGFR (mL/min/1.73 m2 )

105.83 (87.04, 125.03)

106.55 (87.64, 125.79)

100.02 (81.46, 117.84)

< 0.001

 ≥60

4832 (92.3%)

4301 (92.3%)

531 (92.7%)

0.74

 <60

402 (7.7%)

360 (7.7%)

42 (7.3%)

AFP (ng/ml)

4.8 (2.9, 15.45)

4.8 (2.79, 13.34)

8.5 (4.61, 33.7)

< 0.001

 <5.0

2902 (55.4%)

2689 (57.7%)

213 (37.2%)

< 0.001

 ≥5.0

2332 (44.6%)

1972 (42.3%)

360 (62.8%)

PT(s)

13.9 (13.5, 14.9)

13.9 (13.4, 14.9)

14 (13.9, 15.6)

< 0.001

PTA(%)

88 (77, 94)

88 (77, 94)

87 (71, 88)

< 0.001

INR

1.09 (1.04, 1.18)

1.09 (1.04, 1.18)

1.09 (1.09, 1.25)

< 0.001

APTT(s)

38.6 (36.6, 41.4)

38.6 (36.6, 41.4)

38.6 (37.2, 41)

0.70

Glucose(mmol/l)

5.1 (4.6, 6)

5.1 (4.5, 5.9)

5.1 (4.8, 6.7)

< 0.001

HBeAg(+)

506 (43.9%)

452 (43.9%)

54 (43.5%)

0.94

NA

5234

4661

573

0.35

Entecavir

3847

3398(72.9%)

449(71.4%)

Lamivudine

559

494(10.6%)

65(11.3%)

adefovir dipivoxil

351

303(6.5%)

48(8.4%)

Tibivudine

477

466(10.0%)

11(8.9%)

Tenofovir

0

0(0%)

0(0%)